Patrick Soon-Shiong, M.D. Honored as Guest Lecturer at American Urological Association 2016 Annual Meeting

Lecture highlights "Cancer Breakthroughs 2020" Urology to largest worldwide gathering of urologists

San Diego, CA – May 9, 2016 – Patrick Soon-Shiong, M.D., founder and CEO of NantWorks, and leader of the Cancer Breakthroughs 2020 program, will deliver the Ramon Guiteras Lecture, titled "Cancer Breakthroughs 2020 Urology,” at the American Urological Association Annual Meeting, May 6-10, 2016, at the San Diego Convention Center in San Diego, California. Now in its 111th year, the annual AUA meeting brings together urologists and urologic health care professionals worldwide to discuss groundbreaking research, new guidelines and the latest advances in urologic medicine. 

A physician, surgeon, scientist and philanthropist, Dr. Soon-Shiong is a thought leader and pioneer in oncology and molecular science. At the AUA 2016 Annual Meeting, Dr. Soon-Shiong will discuss the need for exploitation of immunotherapy and current breakthroughs in immuno-oncology through the Cancer Breakthroughs 2020 program. Positioned as the next-generation standard of treatment for cancer patients, Dr. Soon-Shiong, in collaboration with some of today’s brightest healthcare leaders, is working to bring combination immunotherapies to cancer patients in an effort to win the war against cancer.

WHO:  Patrick Soon-Shiong M.D., FRCS(C), FACS, chairman and chief executive officer, NantWorks; founder of Cancer Breakthroughs 2020

WHAT:  Ramon Guiteras Lecture: “Cancer Breakthroughs 2020 Urology”

WHEN:  Monday, May 9, 9:10-9:30 a.m. PST

WHERE:  American Urological Association 111th Annual Meeting

San Diego Convention Center

111 W. Harbor Dr.

San Diego, California 92101      

About NantWorks

NantWorks, LLC, is the umbrella organization for an ecosystem of companies committed to the convergence of 21st century innovative platforms to transform how we work, live and play: NantHealth, NantOmics, NantBioScience, NantCell, NantKwest, NantPharma, NantMobile, NantStudio, NantCapital and NantCloud. Fact-based and solution driven, each of NantWorks’ division companies operates at the intersection of innovation and infrastructure. For more information please visit www.nantworks.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

About NantHealth

NantHealth, a member of the NantWorks ecosystem of companies, is a transformational company converging the power of genomic science and healthcare IT through a highly scalable cloud-based platform, to provide actionable health information at the point of care, in the time of need, anywhere, anytime. NantHealth works to transform clinical delivery with actionable clinical intelligence at the moment of decision, enabling clinical discovery through real-time machine learning systems. The company’s technology empowers physicians, patients, payers and researchers to transcend genomics into the world of proteomics and the traditional barriers of today’s healthcare system. By converging molecular science, computer science and big data technology, the Nant Service Oriented Operating System (NantOS) platform empowers physicians, patients, and payers to coordinate best care, monitor outcomes and control cost in real time. This is the first operating system of its kind in healthcare that is based on supply chain principles and grid service oriented architecture and integrates the knowledge base with the delivery system and the payment system, enabling 21st century coordinated care at a lower cost. For more information please visit www.nanthealth.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

About Cancer Breakthroughs 2020

The Cancer Breakthroughs 2020 program is one of the most comprehensive cancer collaborative initiatives launched to date, seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. This initiative aims to explore a new paradigm in cancer care by initiating randomized Phase II trials in patients at all stages of disease in 20 tumor types in 20,000 patients within the next 36 months. These findings will inform Phase III trials and the aspirational Breakthroughs to develop an effective vaccine-based immunotherapy to combat cancer by 2020. For more information, please visit http://www.CancerBreakthroughs2020.org and follow Cancer Breakthroughs 2020 on Twitter

 

Press Contact:

Jen Hodson

NantWorks

jhodson@nantworks.com

562-397-3639